Survey Highlights Critical Need for AI Adoption in Regulatory Affairs Amid Unsustainable Workloads

New research commissioned by ArisGlobal, a provider of life sciences technology solutions, reveals that surging regulatory workloads are forcing life …

Continue ›››

What will be the key trends in AI innovation in the Pharmaceutical Industry in 2025?

The pharmaceutical industry is undergoing transformation thanks to artificial intelligence (AI) in particular GenAI. From drug discovery and manufacturing to …

Continue ›››

Immunai and Teva Collaborate to Advance Clinical Trials in Oncology and Immunology

Immunai, an AI-driven biotech company focused on mapping the human immune system, has partnered with Teva Pharmaceuticals in a multi-year …

Continue ›››

Enveda Advances AI-Discovered, Nature-Derived Drug ENV-294 to Phase 1 Trials

Enveda, a biotechnology company transforming nature’s chemistry into medicines using AI, has announced the FDA clearance of an investigational new …

Continue ›››

Genesis Therapeutics Collaborates with NVIDIA and Secures Additional NVentures Funding to Accelerate AI-Driven Drug Discovery

Genesis Therapeutics has announced a collaboration with NVIDIA to advance its AI platform, GEMS (Genesis Exploration of Molecular Space). The …

Continue ›››

Recursion Unveils OpenPhenom-S/16: A Foundation Model for Microscopy Data

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) has released OpenPhenom-S/16, a new publicly accessible foundation model, on Google Cloud’s Vertex AI Model …

Continue ›››

Schrödinger and Novartis Forge Partnership to Scale Computational Drug Discovery

Schrödinger, Inc. (Nasdaq: SDGR) has entered a collaboration and licensing agreement with Novartis to advance drug discovery efforts on multiple …

Continue ›››

Recursion Unveils New Foundation Model for Molecular Property Prediction

Recursion researchers have introduced MolE, a new model aimed at improving predictions of chemical and biological properties of molecules by …

Continue ›››

AI-Driven Drug Shows Promising Phase IIa Results in Treating Fatal Lung Disease

Insilico Medicine, a biotechnology company that developed foundational artificial intelligence (AI) in drug discovery platform, recently reported promising results from …

Continue ›››

AlphaFold3 Goes Open Source

DeepMind released AlphaFold3’s code, available on GitHub, marking a new stage in AI-based protein structure prediction. AlphaFold3 expands the tool's …

Continue ›››

Tempus AI to Acquire Ambry Genetics for $600 Million

Tempus AI has announced its acquisition of Ambry Genetics, from KONICA MINOLTA, INC. for $600 million, comprising $375 million in …

Continue ›››

BPGbio Presents AI-Guided Immune-Modulating Therapeutics at SITC 2024

BPGbio presented findings at SITC 2024 on two oncology drug candidates, BPM31510 and BRG399, aimed at advancing immune-based cancer treatments.

Continue ›››